Director, ECD Development New San Carlos, CA

Natera, Inc.; San Carlos (CA); Remote; USD 229,000 - 286,000; Full time

Benefits offered by this job

Competitive Benefits

Free testing for employees and depend.

Pregnancy and baby bonding leave

401k benefits

Commuter benefits

Employee referral program

Job summary

Natera, Inc. is seeking a Director of Development to own the end-to-end development and regulatory strategy for our Early Cancer Detection (ECD) IVD products.

You will drive design verification and validation from feasibility through PMA submission, serving as the FDA SME and leading a team of scientists and managers. You will oversee analytical performance strategies, coordinate with Regulatory Affairs, biostatistics, and research, and ensure successful technology transfer to commercial labs

Qualifications

• Advanced degree (PhD, MD, or equivalent) or MS with relevant industry experience
• 6+ years of experience in IVD or diagnostic device development under design controls
• 5+ years directing scientific or technical teams
• Deep technical expertise with NGS-based diagnostic assays and analytical validation
• Experience with FDA interactions for molecular diagnostics or NGS devices

Responsibilities

• Own the technical strategy and phase-gated development for ECD IVD devices
• Ensure compliance with FDA Class III PMA design and development requirements
• Lead analytical performance strategy for ECD assays and collaborate with RA, biostatistics, and bioinformatics
• Transfer assays to commercial labs and manufacturing
• Partner on statistical analysis plans for approvable device performance claims
• Deliver data-backed updates to FDA and leadership
• Build and mentor a high-performing organization and manage budgets and vendors

Skills

Team leadership

FDA interactions

NGS diagnostics

Regulatory knowledge

Cross-functional collaboration

Education

PhD/MD or MS with experience

Tools

Bioinformatics pipelines

IEC 62304

Job description

Join Natera as the Director of Development for our Early Cancer Detection (ECD) In Vitro Diagnostic (IVD) products. You will take ownership of the development, verification, and validation of our early cancer detection (ECD) Next Generation Sequencing products from feasibility exit through regulatory submission and post-market support. Every test represents a real person, and you will lead a team of scientists and managers to execute the performance data packages supporting PMA submissions. You will serve as the technical subject matter expert in FDA interactions, partnering across functions to deliver design-controlled diagnostic products that directly impact patient care.

PRIMARY RESPONSIBILITIES:

• Own the execution of the technical strategy and phase-gated process of of development, design verification, and validation studies for ECD IVD devices utilizing cfDNA, methylation and other potential analytes
• Ensure rigorous compliance with applicable FDA Class III (PMA) design and development requirements
• Take ownership of the analytical performance strategy (limit of blank/detection, precision, linearity, interference, stability) for ECD assays, partnering directly with Regulatory Affairs (RA), biostatistics, bioinformatics and research teams
• Contribute to the robust transfer of assays to the commercial laboratory and manufacturing in support of the design transfer and operations teams
• Partner with clinical and biostatistics leaders on statistical analysis plans required for approvable device performance claims in clinical intended-use populations
• Think team by partnering directly across bioinformatics, biostatistics, software engineering, clinical, regulatory, and commercial functions to align development efforts with business goals, and drive resourcing and go/no-go recommendations at phase gates
• Deliver the analytical performance data package supporting Class III PMA submissions, developing a comprehensive approval strategy with RA
• Serve as the technical subject matter expert in correspondence and meetings with the FDA, defending performance evidence using data
• Treat Quality Management System (QMS) requirements (ISO 13485:2016, FDA QMSR 21 CFR Part 820, ISO 14971, IEC 62304) and regulatory guidance as the foundation of product development rather than a final check
• Build, develop, and retain a high-performing organization of scientists and managers, optimizing program budgets and external vendor partnerships
• Use data to identify technical and timeline risks, including ISO 14971 risk management deliverables, making risk-based decisions on mitigation and escalation

REQUIRED QUALIFICATIONS:

• Advanced degree (PhD, MD, or equivalent) in Molecular Biology, Biomedical Engineering, Life Sciences, or a related field; an MS with additional relevant industry experience will be considered
• 6+ years of experience in IVD or diagnostic device development under design controls
• 5+ years of experience directing scientific or technical teams

KNOWLEDGE, SKILLS, AND ABILITIES:

• Deep technical expertise with complex NGS-based diagnostic assays, including assay design, analytical validation, and transfer to a commercial laboratory or manufacturing
• Demonstrated direct experience in FDA interactions (e.g., Pre-Submission meetings) for a molecular diagnostic or NGS-based device
• Experience in liquid biopsy or molecular diagnostics for clinical oncology, specifically cfDNA-based detection of low-abundance signals at high specificity
• Push for clarity and outcome-driven action across the organization, with a solutions-oriented approach to both technical challenges and cross-functional team dynamics
• Working knowledge of FDA premarket pathways for high-complexity IVD approvals
• Deep knowledge of FDA regulations (21 CFR Part 820/QMSR, Part 809, and Part 814), ISO 13485:2016, ISO 14971, and IVDR
• Deliver unvarnished, data-backed updates to internal and external stakeholders (including the FDA and executive leadership), pushing for decisions grounded in analytical evidence
• Ability to translate the requirements of device development to technical and non-technical teams, enabling robust development processes and performance study designs

PREFERRED QUALIFICATIONS:

• Served as a principal technical contributor on a PMA, De Novo, or Breakthrough Device submission for an NGS-based oncology device, or an equivalent high-complexity IVD approval outside the US (e.g., IVDR Class C/D, PMDA, NMPA)
• Experience with pivotal clinical validation studies for cancer screening or early detection, in partnership with biostatistics
• Experience translating Laboratory Developed Tests (LDTs) into FDA-regulated IVD products
• Experience with bioinformatics pipelines and companion software as components of a regulated IVD (IEC 62304)

Remote USA

$228,600 - $285,800 USD

OUR OPPORTUNITY

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives.

The Natera team consists of highly dedicated statisticians, geneticists, doctors, laboratory scientists, business professionals, software engineers and many other professionals from world-class institutions, who care deeply for our work and each other. When you join Natera, you’ll work hard and grow quickly. Working alongside the elite of the industry, you’ll be stretched and challenged, and take pride in being part of a company that is changing the landscape of genetic disease management.

WHAT WE OFFER

• Competitive Benefits - Employee benefits include comprehensive medical, dental, vision, life and disability plans for eligible employees and their dependents.
• Additionally, Natera employees and their immediate families receive free testing in addition to fertility care benefits.
• Other benefits include pregnancy and baby bonding leave, 401k benefits, commuter benefits and much more.
• We also offer a generous employee referral program!

Natera is proud to be an Equal Opportunity Employer. We are committed to ensuring a diverse and inclusive workplace environment, and welcome people of different backgrounds, experiences, abilities and perspectives. Inclusive collaboration benefits our employees, our community and our patients, and is critical to our mission of changing the management of disease worldwide.

All qualified applicants are encouraged to apply, and will be considered without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, age, veteran status, disability or any other legally protected status. We also consider qualified applicants regardless of criminal histories, consistent with applicable laws.

If you are based in California, we encourage you to read this important information for California residents.

Please be advised that Natera will reach out to candidates with a @ natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes.

Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey.Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiringprocess or thereafter. Any information that you do provide will be recorded and maintained in aconfidential file.

As set forth in Natera’s Equal Employment Opportunity policy,we do not discriminate on the basis of any protected group status under any applicable law.

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection.As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measurethe effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categoriesis as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.